Research
Metabolic adaptation
All secondary cardiometabolic outcomes improved significantly throughout the study.
Practitioners can consider compounded GLP-1 ± GIP agonists as effective for improving various cardiometabolic risk factors.
StrongSupportsmedium confidence
All secondary cardiometabolic outcomes improved significantly throughout the study.
Why this rating
Based on the retrospective cohort study design with a clear outcome measure.
Source
Real‐world observations of using compounded <scp>GLP</scp> ‐1 ± <scp>GIP</scp> agonists within a clinical pharmacist‐managed cardiometabolic clinic
Shannon W. Finks et al. · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2025
cohort · n=50Cited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →